LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Inicio・Lista de Acciones・Lisata Therapeutics

L
Lisata Therapeutics

Cerrado

2.06 -10.43

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.03

Máximo

2.12

Métricas clave
By Trading Economics
Empleados	26

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+628.16% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-71K 20M
Apertura anterior	12.49
Cierre anterior	2.06

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 nov 2025, 21:06 UTC

Principales Movimientos del Mercado

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8 nov 2025, 18:10 UTC

Ganancias

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

8 nov 2025, 13:10 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 12:00 UTC

Ganancias

Apple's iPhone Air Is a Marketing Win and a Sales Flop -- WSJ

8 nov 2025, 10:30 UTC

Ganancias

Why Car Insurers Are Under Pressure to Cut Rates -- Heard on the Street -- WSJ

8 nov 2025, 03:50 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Ganancias

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Ganancias

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov 2025, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 nov 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

7 nov 2025, 20:59 UTC

Ganancias

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov 2025, 20:26 UTC

Charlas de Mercado

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov 2025, 20:22 UTC

Ganancias

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov 2025, 20:04 UTC

Charlas de Mercado

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov 2025, 19:34 UTC

Charlas de Mercado

Gold Posts Small Gain for Week -- Market Talk

7 nov 2025, 19:31 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov 2025, 19:17 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov 2025, 19:09 UTC

Ganancias

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov 2025, 19:08 UTC

Ganancias

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov 2025, 18:31 UTC

Charlas de Mercado

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov 2025, 17:27 UTC

Charlas de Mercado

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Precio Objetivo

By TipRanks

628.16% repunte

Estimación a 12 meses

Media 15 USD 628.16%

Máximo 15 USD

Mínimo 15 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lisata Therapeutics Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Lisata Therapeutics Dist en los últimos 3 meses.

Finanzas

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.